GenMark Diagnostics (GenMark Diagnostics) Growth Rank : 0 (As of May. 05, 2024)

View and export this data going back to 2010. Start your Free Trial

What is GenMark Diagnostics Growth Rank?

GenMark Diagnostics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

GenMark Diagnostics Growth Rank Related Terms

Thank you for viewing the detailed overview of GenMark Diagnostics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

GenMark Diagnostics (GenMark Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » GenMark Diagnostics Inc (NAS:GNMK) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

5964 La Place Court, Carlsbad, CA, USA, 92008-8829

Website

http://www.genmarkdx.com

GenMark Diagnostics Inc is a provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. The company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales, and support of instruments and molecular tests based on its proprietary eSensor detection technology. Its operations and assets are in the United States of America.

Executives

Tyler Jensen	officer: SVP, Engineering and Tech Dev	5964 LA PLACE COURT CARLSBAD CA 92008
Christine Shaw	officer: VP, Assay Development	5964 LA PLACE COURT CARLSBAD CA 92008
Alan Baer Maderazo	officer: VP, Qual, Reg, & Clin Affairs	5964 LA PLACE COURT CARLSBAD CA 92008
Michael Gleeson	officer: SVP, Corp. Accounts	5964 LA PLACE COURT, SUITE 100 CARLSBAD CA 92008
Sarah Hollis Winkler	officer: VP, Human Resources	5964 LA PLACE COURT CARLSBAD CA 92008
Michael John Harkins	officer: SVP, Sales	5964 LA PLACE COURT CARLSBAD CA 92008
John Frederick Ek	officer: Chief Financial Officer	5964 LA PLACE COURT, CARLSBAD CA 92008
Scott Mendel	director, officer: President & CEO	5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008
Eric Stier	officer: SVP & General Counsel	5964 LA PLACE COURT CARLSBAD CA 92008
Brian Andrew Mitchell	officer: SVP, Operations	5964 LA PLACE COURT CARLSBAD CA 92008
Daryl Faulkner	director	5964 LA PLACE COURT, CARLSBAD CA 92008
Michael Kagnoff	director	DLA PIPER LLP (US) 4365 EXECUTIVE DRIVE, SUITE 1100 SAN DIEGO CA 92121
Lisa M. Giles	director	DURATA THERAPEUTICS, INC., 200 SOUTH WACKER DRIVE SUITE 2550, CHICAGO IL 60606
Kevin C Oboyle	director	5964 LA PLACE COURT, CARLSBAD CA 92008
James Fox	director	5964 LA PLACE COURT, CARLSBAD CA 92008